

DPP-4/SGLT2 INHIBITORS / GLP-1 RECEPTOR AGONISTS SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

PATENT LAST NAME	PATIENT INFORMATION							COVERA	AGE TYPE			
ALBERTA PERSONAL HEALTH NUMBER			FIRST NAME	FIRST NAME			INITIAL	Alber	ta Blue Cross			
STREET ADDRESS CITY PROV POSTAL CODE IDICLIENT/COVERAGE NUMBER	DIDTH DATE	L DATE (VVVV/MM/DD) ALBERTA REDSONALUE			ALTU NUMBER			1 				
PRESCRIBER INFORMATION PRESCRIBER LAST NAME FIRST NAME FAX NUMBER Corken FAX NUMBER CORN CORP FAX NUMBER COMPLETE FAX NUMBER CORN CORP FAX NUMBER FAX NUMBER CORN CORP FAX NUMBER COMPLETE COMPLETE FAX NUMBER COMPLETE FAX NUMBER COMPLETE COMPLETE COMPLETE FAX NUMBER COMPLETE COMPLETE COMPLETE FAX NUMBER COMPLETE COMPLETE COMPLETE COMPLETE COMPLETE FAX NUMBER COMPLETE COMPLETE C	BIKTH DATE	IN DATE (TITT/MIN/DD) ALBERTA PERSONAL HEA				JIVIDER	•	Other	-			
PRESCRIBER LAST NAME FIRST NAME INITIAL PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION NUMBER CARNA ACD ACD REGISTRATION NUMBER ADA-CC ACP ADA-CC ACP Other FAX ACD ACD Other FAX FAX ACD Other FAX FAX ACD Other FAX	STREET ADDR	STREET ADDRESS CITY PI			ROV POSTAL CODE ID/CLIENT/C				NT/COVERA	AGE NUMBER		
PRESCRIBER LAST NAME FIRST NAME INITIAL PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION NUMBER CARNA ACD ACD REGISTRATION NUMBER ADA-CC ACP ADA-CC ACP Other FAX ACD ACD Other FAX FAX ACD Other FAX FAX ACD Other FAX												
STREET ADDRESS GARNA ACO REGISTRATION NUMBER GARNA ADDA+C ACP ACP Other FAX ACC ACP ACP ACP Other FAX ADDA+C ACP A			FIDET NAME IN	ITIAI	DDEC	CDIDE		CIONAL AS	CCOCIATIO	N DECISTRATION		
STREET ADDRESS GARN GAPA	PRESCRIBER	LAST NAME	FIRST NAME IN	IIIAL								
PHONE	STREET ADDRESS											
POSTAL CODE FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED												
Indicate which drug is requested For the treatment of Type 2 diabetes Criteria for coverage* Complete section(s)	CITY, PROVINCE				PHONE FAX							
Can Agilfilozin (e.g. Invokana) SAXXAgliptin + metformin Can Agilfilozin (e.g. Invokana) SAXXAgliptin + metformin Can Agilfilozin (e.g. Irrajenta) Can Agilfilozin (e.g. Trajenta) Can Agilfilozin (e.g. Trajenta) Can Komboglyze) SEMAgliutide (e.g. Ozempic) SemAgliutide (e.g. Januvia) SemAgliutide (e.g. Januvia) SaxxAgliptin (e.g. Forxiga) Can Januvia SaxxAgliptin (e.g. Forxiga) Can Januvia Can Januvia SaxxAgliptin (e.g. Forxiga) Can Januvia SaxxAgliptin + metformin Can Januvia Can Januvia Can Jan	POSTAL CODE						FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED					
CANAgliflozin (e.g. Invokana)	Indicate which drug is requested											
LINAgliptin (e.g. Trajenta) (e.g. Komboglyze) SEMAglutide (e.g. Ozempic) (e.g. Jentadueto) SITAgliptin (e.g. Januwia) SITAgliptin (e.g. Janumet, Janumet XR) DAPAgliflozin (e.g. Forxiga) DAPAgliflozin + metformin (e.g. Xigduo) Sitagen Second-line drug product(s): metformin or sulfonylureas Second-line drug product(s): metformin or sulfonylureas Second-line drug product(s): metformin Second-line drug produc	For the treatment of Type 2 diabetes					a for c	overage*	Complete section(s)				
LINAgliptin + metformin SEMAglutide (e.g. Ozempic) Sections I & II	CANAgliflozin (e.g. Invokana) SAXAgliptin + metformin											
Complete sections & II	LINAgliptin (e.g. Trajenta) (e.g. Komboglyze)				3 . ()							
SAXAgliptin (e.g. Onglyza) SITAgliptin (e.g. Januwia) SAXAgliptin (e.g. Janumet XR)	LINAgliptii	☐ LINAgliptin + metformin ☐ SEMAglutide (e.g. Ozempic)					Sulin is no	1	Sections I & II			
DAPAgliflozin (e.g. Forxiga)		·	- ' ' -)								
DAPAgliflozin (e.g. Forxiga) DAPAgliflozin + metformin (e.g. Xigduo) DAPAgliflozin + metformin (e.g. Xigduo) DAPAgliflozin + metformin (e.g. Xigduo) DAPAgliflozin + metformin (e.g. Xigduo) DAPAgliflozin + metformin (e.g. Xigduo) DAPAgliflozin + metformin (e.g. Xigduo) DAPAgliflozin + metformin And where insulin is not an option LIXIsenatide (e.g. Adlyxine) First-line drug product(s): metformin Second-line drug product(s): sulfonylureas Sections I & II For the treatment of Type 2 diabetes OR Type 2 diabetes and established CV diseases as defined in the criteria for coverage Criteria for coverage* Complete section(s) EMPAgliflozin EMPAgliflozin + metformin *See page 2 for complete criteria Sections I & II (as applicable) Section I. Please indicate if metformin was tried for at least 6 months Yes No, specify reason Please indicate if a sulfonylurea was tried Yes No, specify reason Please indicate if insulin was tried Manual dexterity concerns Visual impairment Manual dexterity concerns Visual impairment Manual dexterity concerns Visual impairment DATE (YYYY-MM-DD) Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton *1-877-828-4106 toll free all other areas												
DAPAgliflozin + metformin (e.g. Xigduo) DAPAgliflozin + metformin (e.g. Xigduo) metformin or sulfonylureas Second-line drug product(s): sulfonylureas or metformin And where insulin is not an option			(e.g. Janumet, Janumet					`				
Second-line drug product(s): sulfonylureas or metformin And where insulin is not an option LIXIsenatide (e.g. Adlyxine) First-line drug product(s): metformin Second-line drug product(s): sulfonylureas And insulin For the treatment of Type 2 diabetes OR Type 2 diabetes and established CV diseases as defined in the criteria for coverage EMPAgliflozin EMPAgliflozin + metformin (e.g. Jardiance) EMPAgliflozin + metformin (e.g. Synjardy) *See page 2 for complete criteria Sections I & II (as applicable) Section I. Please indicate if metformin was tried for at least 6 months Yes No, specify reason Section II. Please indicate if a sulfonylurea was tried Yes No, specify reason Please indicate if insulin was tried Yes No, indicate why insulin is not an option for this patient Manual dexterity concerns Needle phobia Visual impairment Needle phobia Visual impairment Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas												
or metformin And where insulin is not an option LIXIsenatide (e.g. Adlyxine) First-line drug product(s): metformin Second-line drug product(s): sulfonylureas And insulin For the treatment of Type 2 diabetes OR Type 2 diabetes and established CV diseases as defined in the criteria for coverage EMPAgliflozin EMPAgliflozin + metformin (e.g. Jardiance) EMPAgliflozin + metformin (e.g. Synjardy) Section I. Please indicate if metformin was tried for at least 6 months Yes	DAPAgliflozin + metformin (e.g. Xigduo)				-					Sections I & II		
LIXIsenatide (e.g. Adlyxine)						formin						
Sections I & II For the treatment of Type 2 diabetes OR Type 2 diabetes and established CV diseases as defined in the criteria for coverage EMPAgliflozin						-						
And insulin For the treatment of Type 2 diabetes OR Type 2 diabetes and established CV diseases as defined in the criteria for coverage EMPAgliffczin	LIXIsenatide (e.g. Adlyxine)							Sections I & II				
## Complete section(s) EMPAglistoria							irug produ	Sections I & II				
EMPAgliflozin						a for c	ovorago*	Complete section(s)				
Ce.g. Jardince (e.g. Synjardy) (as applicable) Section I.												
Section I. Please indicate if metformin was tried for at least 6 months Yes	—			iin	*See p	age 2	for comple	te criteria				
Section II. Please indicate if a sulfonylurea was tried Yes No, specify reason Please indicate if insulin was tried Yes No, indicate why insulin is not an option for this patient Cognitive impairment Needle phobia Other, specify PRESCRIBER'S SIGNATURE DATE (YYYY-MM-DD) Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas	, ,	, (3,7,7,7)								(as applicable)		
Please indicate if a sulfonylurea was tried Yes	Section i.											
Please indicate if insulin was tried Yes No, indicate why insulin is not an option for this patient Cognitive impairment Manual dexterity concerns Needle phobia Visual impairment Other, specify PRESCRIBER'S SIGNATURE DATE (YYYY-MM-DD) Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas												
Please indicate if insulin was tried Yes	Section II.	Please indicate if a sulfonylurea was tried										
PRESCRIBER'S SIGNATURE DATE (YYYY-MM-DD) PRESCRIBER'S SIGNATURE DATE (YYYY-MM-DD) PRESCRIBER'S SIGNATURE PRESCRIBER'S SIGNATURE DATE (YYYY-MM-DD) Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas		☐ Yes ☐ No, specify reason										
Cognitive impairment Manual dexterity concerns Visual impairment Visual impairment Visual impairment Visual impairment Other, specify Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas		Please indicate if insulin was tried										
Needle phobia												
PRESCRIBER'S SIGNATURE DATE (YYYY-MM-DD) Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas												
PRESCRIBER'S SIGNATURE DATE (YYYY-MM-DD) Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas			•		」 Visu	al impa	airment					
 Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas 		1		1								
10009-108 Street NW, Edmonton, Alberta T5J 3C5 ■ FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas	PRESCRIBER'S	SIGNATURE	DATE (YYYY-MM-DD)									
				1	10009-1	08 Stre	et NW, Edn	nonton, Al	berta T5J			
ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.		ONCE YOUR REQUEST W	C CLICCECCEUL V TRANC									

The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 108 Street, Edmonton AB T5J 3C5.







Criteria for coverage

DPP-4/SGLT2 INHIBITORS / GLP-1 RECEPTOR AGONISTS SPECIAL AUTHORIZATION CRITERIA

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

CANAgliflozin (e.g. Invokana), LINAgliptin (e.g. Trajenta), LINAgliptin + metformin (e.g. Jentadueto), LIXIsenatide (e.g. Adlyxine), SAXAgliptin (e.g. Onglyza), SAXAgliptin + metformin (e.g. Komboglyze), SEMAglutide (e.g. Ozempic), SITAgliptin (e.g. Januvia) and SITAgliptin + metformin (e.g. Janumet, Janumet XR) special authorization criteria

FIRST-LINE DRUG PRODUCT(S): METFORMIN SECOND-LINE DRUG PRODUCT(S): SULFONYLUREAS AND WHERE INSULIN IS NOT AN OPTION

As add-on therapy for the treatment of Type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on:

- a sufficient trial (i.e. a minimum of 6 months) of metformin. AND
- a sulfonylurea, AND
- for whom insulin is not an option.

Or, for whom these products are contraindicated.

Special authorization may be granted for 24 months

DAPAgliflozin (e.g. Forxiga) and DAPAgliflozin + metformin (e.g. Xigduo) special authorization criteria for the treatment of Type 2 diabetes

Note: Dapagliflozin (e.g. Forxiga) is also eligible via special authorization/step therapy for the treatment of heart failure. Please refer to the Alberta Drug Benefit List for the complete criteria and to the Dapagliflozin for Heart Failure Special Authorization Request Form (ABC 60097).

FIRST-LINE DRUG PRODUCT(S): METFORMIN OR SULFONYLUREAS SECOND-LINE DRUG PRODUCT(S): SULFONYLUREAS OR METFORMIN AND WHERE INSULIN IS NOT AN OPTION

As add-on therapy to metformin or a sulfonylurea for the treatment of Type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on:

- a sufficient trial (i.e. a minimum of 6 months) of metformin who have a contraindication or intolerance to a sulfonylurea, OR a sulfonylurea who have a contraindication or intolerance to metformin,
- AND for whom insulin is not an option.

Special authorization may be granted for 24 months.

EMPAgliflozin (e.g. Jardiance) and EMPAgliflozin + metformin (e.g. Synjardy) special authorization criteria

FIRST-LINE DRUG PRODUCT(S): METFORMIN

As add-on therapy for the treatment of Type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on:

- a sufficient trial (i.e. a minimum of 6 months) of metformin, AND
- a sulfonylurea, AND
- for whom insulin is not an option.

Or, for whom these products are contraindicated.

As an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular diseases who have an inadequate glycemic control, if the following criteria are met:

- a sufficient trial (i.e. a minimum of 6 months) of metformin, AND
- established cardiovascular disease* as defined in the EMPA-REG OUTCOME trial.
- * Established cardiovascular disease is defined on the basis of one of the following:
- 1) History of myocardial infarction (MI)
- 2) Multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)
- 3) Single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress or discharged from hospital with a documented diagnosis of unstable angina within the last 12 months
- 4) Last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease
- 5) History of ischemic or hemorrhagic stroke
- 6) Occlusive peripheral artery disease

Special authorization may be granted for 24 months.

LIXIsenatide (e.g. Adlyxine) special authorization criteria

FIRST-LINE DRUG PRODUCT(S): METFORMIN SECOND-LINE DRUG PRODUCT(S): SULFONYLUREAS AND INSULIN

"As add-on therapy for the treatment of Type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on:

- a sufficient trial (i.e. a minimum of 6 months) of metformin, AND
- a sulfonylurea, AND
- insulin.

Or, for whom these products are contraindicated

Special authorization may be granted for 24 months.

